Halozyme Therapeutics Names Matt Posard to Board of Directors

        Halozyme Therapeutics Names Matt Posard to Board of Directors

PR Newswire

SAN DIEGO, March 28, 2013

SAN DIEGO, March 28, 2013 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:
HALO) today announced the appointment of Matt Posard to its Board of
Directors. Mr. Posard is currently Senior Vice President and General Manager
of Translational & Consumer Genomics at Illumina, Inc.

(Logo: http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)

"We welcome Matt to our Board of Directors. His strategic marketing experience
will complement Halozyme's Board well as we increase our commercial activities
with Hylenex," said Gregory I. Frost, Ph.D., President and Chief Executive
Officer at Halozyme.

Mr. Posard has over two decades of experience in strategic and product
marketing. He joined Illumina in 2006 as Vice President of Global Marketing
and served as Vice President of Global Sales from 2007 to 2011, leading
Illumina's successful commercial entry into the life science sequencing market
where it now holds significant market share alongside the company's array
business. Prior to joining Illumina, he held a variety of positions with the
product marketing team at Gen-Probe, Inc., helping the company attain leading
market positions in DNA probe-based infectious disease diagnostics and blood
banking. He also oversaw global marketing at Biosite, Inc., where he was
instrumental in the successful introduction of the company's BNP congestive
heart failure biomarker and its BNP co-marketing collaboration with Beckman
Coulter. Mr. Posard holds a Bachelor of Arts degree in Quantitative Economics
and Decision Science from the University of California, San Diego.

AboutHalozyme Therapeutics
Halozyme Therapeuticsis a biopharmaceutical company dedicated to developing
and commercializing innovative products that advance patient care. With a
diversified portfolio of enzymes that target the extracellular matrix, the
Company's research focuses primarily on a family of human enzymes, known as
hyaluronidases, which increase the absorption and dispersion of biologics.
Halozyme's pipeline addresses therapeutic areas, such as diabetes, oncology
and dermatology that have significant unmet medical need. The Company markets
Hylenex® recombinant (hyaluronidase human injection) and has partnerships
withRoche,Baxter,ViroPharma, Intrexon, and Pfizer. Halozyme is
headquartered inSan Diego, CA.For more information on how we are innovating,
please visit our corporate website atwww.halozyme.com.



Investor Contact:
Kurt Gustafson
Halozyme Therapeutics
858-704-8272
ir@halozyme.com

Media Contact:
Nurha Hindi
Hill + Knowlton Strategies
310-633-9434
Nurha.Hindi@hkstrategies.com

SOURCE Halozyme Therapeutics, Inc.

Website: http://www.halozyme.com
 
Press spacebar to pause and continue. Press esc to stop.